ERBB2 and neoplasm: This could be partially explained by the fact that the number of patients derived from the public dataset carrying a triple negative tumor was relatively low (68 N-CadherinLow and 27 N-CadherinHigh samples) and the absence of triple positive specimens in our BrCa tissue array forced us to compare the triple negative samples only with the ER, PR and HER2 single negative tumors.